Oxervate Market Report 2026

Oxervate Market Overview

• The Oxervate market growth in the historic period has been driven by increasing diagnosis of neurotrophic keratitis, limited availability of effective corneal repair therapies • Market expansion is supported by expansion of regenerative ophthalmology research, rising investments in rare eye disease therapeutics • Growth Driver: Rising Incidence Of Eye Inflammation Disorders Fueling Growth In The Market • North America was the largest region in 2025.

What Is Covered Under Oxervate Market?

Oxervate (cenegermin-bkbj) is a prescription ophthalmic solution used to treat neurotrophic keratitis, a rare degenerative condition that affects the cornea. It contains cenegermin, a recombinant human nerve growth factor (rhNGF), which helps repair and regenerate corneal tissue by promoting the survival and growth of corneal nerves. The main clinical indications of oxervate are neurotrophic keratitis, and dry eye disease (DED). Neurotrophic keratitis is a rare, progressive corneal disease caused by nerve damage, leading to impaired healing, chronic dryness, and potential ulceration. It is distributed by several distribution channels such as retail pharmacies, and online pharmacies, and used by various end users, including hospitals, ophthalmology clinics, and home care.

What Is The Oxervate Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of regenerative ophthalmology research, rising investments in rare eye disease therapeutics, increasing adoption of biologics in ophthalmology, growing awareness among eye care professionals, expansion of specialty pharmacy distribution. Major trends in the forecast period include increasing adoption of recombinant growth factor therapies, rising focus on rare ophthalmic disease treatments, expansion of targeted corneal regeneration solutions, growing emphasis on precision biologics manufacturing, enhanced cold-chain handling for biologic eye drops.

Global Oxervate Market Segmentation

1) By Clinical Indication: Neurotrophic Keratitis, Dry Eye Disease (DED) 2) By Distribution Channel: Retail Pharmacies, Online Pharmacies 3) By End User: Hospitals, Ophthalmology Clinics, Home Care

What Are The Drivers Of The Oxervate Market?

The growing incidence of eye inflammation disorders is expected to propel the growth of the oxervate market going forward. Eye inflammation disorders are conditions where the tissues of the eye become swollen and irritated, often causing pain, redness, and vision problems. Eye inflammation disorders are increasing due to factors such as environmental pollution, increased screen time, allergies, and a growing aging population. Oxervate aids in treating eye inflammation disorders by delivering a recombinant form of nerve growth factor (NGF), which promotes the healing of corneal tissue, reduces inflammation, and improves nerve function, aiding in the restoration of the eye's protective barrier. For instance, in May 2024, according to the GOV.UK, a UK-based government website, in the financial year ending 2023, England recorded over 8.9 million vision outpatient attendances, representing a rate of 15,362 per 100,000 population, an increase compared to the previous year. Therefore, the growing incidence of eye inflammation disorders is driving the growth of the oxervate industry. The rising geriatric population is expected to accelerate the growth of the oxervate market going forward. The geriatric population refers to individuals who are aged 65 and older, typically considered to be in the later stages of life and often facing age-related health challenges. The rising geriatric population is attributed to advancements in healthcare, improved living standards, and better access to medical treatments. Oxervate benefits the geriatric population by improving corneal nerve regeneration and reducing the risk of corneal damage in individuals with neurotrophic keratitis, a condition often found in older adults due to age-related changes in the nervous system. For instance, in July 2024, according to the UK Parliament's House of Commons Library, a UK-based government administration, in 2022, 12.7 million people in the UK were aged 65 or older, accounting for 19% of the total population. This figure is projected to rise to 22.1 million by 2072, representing 27% of the country's population. Therefore, the rising geriatric population is driving the growth of the oxervate industry. The growing adoption of personalized medicine is expected to boost the growth of the oxervate market going forward. Personalized medicine is a healthcare strategy that develops treatment plans and therapies based on an individual’s unique biological characteristics, daily habits, and environmental influences to enhance treatment effectiveness and patient outcomes. The widespread adoption of personalized medicine is attributed to advancements in genomics, increased availability of patient-specific data, and the development of targeted therapies. Oxervate aids personalized medicine by focusing on specific biomarkers and customizing treatment plans for individual patients, especially in the management of rare eye diseases such as neurotrophic keratitis, enhancing treatment effectiveness based on each patient's unique condition and response. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based organization, in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, up from six in 2022. Therefore, the growing adoption of personalized medicine is driving the growth of the oxervate industry.

Key Players In The Global Oxervate Market

Major companies operating in the oxervate market are Dompé Farmaceutici S.p.A.

Regional Insights

North America was the largest region in the oxervate market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Oxervate Market?

The oxervate market consists of sales of eye drops. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Oxervate Market Report 2026?

The oxervate market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the oxervate industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.